Clinical trials
Every registered trial of Lixisenatide
61 studies, 1 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Lixisenatide has a real but limited body of human research.
- 61 registered studies in total.
- 1 is still enrolling people, so this is active research, not just history.
What kind of research
- 55 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 21,458 people took part in those.
- A further 6 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.
How far along it is
- 38 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 36 have published results in the medical literature that anyone can read.
- The research spans 64 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 61 of 61 trials for Lixisenatide.
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University
Cardiovascular Kidney Metabolic Syndrome
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
Medical University of Warsaw
Steroid-Induced Diabetes · Steroid-Induced Hyperglycemia · Diabetes
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Type2diabetes
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
The Effect of Lixisenatide on the Effect of Pituitary Hormones
University of Tartu
Healthy · Type 1 Diabetes
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
Jose Seijas Amigo
Weight Loss · Diabetes Mellitus, Type 2 · Quality of Life · Safety Issues
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Sanofi
Type 2 Diabetes Mellitus
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital
Cardiovascular Events · Type2 Diabetes · Renal Disease
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Sanofi
Type 2 Diabetes Mellitus
GLP-1 REceptor Agonists and Real World EvIdeNce
University of Padova
Type 2 Diabetes
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
University Hospital, Toulouse
Parkinson Disease
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2 · Cardiovascular Diseases
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Sanofi
Type 2 Diabetes Mellitus
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
Population Health Research Institute
Type 2 Diabetes Mellitus
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
Sanofi
Type 2 Diabetes Mellitus
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Sanofi
Diabetes Mellitus, Type 2
Lixisenatide arterial stiffness trial (LAST)
King’s College London and Guy’s and St Thomas’ NHS Foundation Trust
Diabetes mellitus
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
Laniado Hospital
Diabetes Mellitus Type 2
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Sanofi
Type 2 Diabetes Mellitus
Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain
Seoul National University Hospital
Diabetes Mellitus
The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects
University Hospital, Gentofte, Copenhagen
Diabetes After Total Pancreatectomy
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Sanofi
Type II Diabetes Mellitus
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
Medical University of Vienna
Type 2 Diabetes Mellitus
Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
Erasme University Hospital
Type 2 Diabetes · Incretinomimetics · Pancreas
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
Hospital Universitari Vall d'Hebron Research Institute
Diabetes Mellitus Type 2
Effect of LIXIsenatide on the Renal System
Amsterdam UMC, location VUmc
Diabetic Kidney Disease · Diabetic Nephropathy · Diabetes Mellitus · Glucagon-Like Peptide 1
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
Sanofi
Type 2 Diabetes Mellitus
The effect of lixisenatide in type 1 diabetes
University of Oxford (UK)
Topic: Diabetes; Subtopic: Type 1 ; Disease: Diabetic Control
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
University of Padova
Type 2 Diabetes
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Sanofi
Type 2 Diabetes
Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes
University of Surrey
Type 2 Diabetes
Study on Lixisenatide and Counterregulation to Hypoglycemia
Lund University
Type 2 Diabetes
Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
Sanofi
Type 2 Diabetes Mellitus
Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People
Royal Adelaide Hospital
Diabetes Mellitus · Gastroparesis
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/S
Diabetes · Diabetes Mellitus, Type 2
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Sanofi
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Sanofi
Type 2 Diabetes
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
Sanofi
Type 2 Diabetes Mellitus
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
Sanofi
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Sanofi
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Sanofi
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
Sanofi
Type 2 Diabetes Mellitus
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
Sanofi
Type 1 Diabetes Mellitus
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Sanofi
Acute Coronary Syndrome
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
Sanofi
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
Sanofi
Type 2 Diabetes Mellitus
Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
Sanofi
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
Sanofi
Diabetes Mellitus, Type 2
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
Sanofi
Type 2 Diabetes
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Lixisenatide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.